nach oben

Erschienen in:

21.07.2023 | Clinical trial

Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry

verfasst von: Yayoi Adachi, Sota Asaga, Hiraku Kumamaru, Naoko Kinugawa, Yasuaki Sagara, Naoki Niikura, Hiromitsu Jinno, Shigehira Saji, Masakazu Toi

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Many studies have shown that the prognosis of invasive lobular carcinoma (ILC) is better than that of invasive ductal carcinoma (IDC). However, both disorders exhibit different prognoses according to molecular subtype, and the prognosis of ILC subtypes might depend on their hormone receptor positivity rate. This study clarified the prognosis of ILC and IDC in each subtype and examined the effectiveness of adjuvant chemotherapy (CT) in luminal ILC.

Methods

We planned the analysis using data from the Breast Cancer Registry in Japan. Because it was presumed that there are differences in characteristics between ILC and IDC, we created matched cohorts using exact matching to compare their prognoses. We compared the prognosis of ILC and IDC for each subtype. We also compared the prognosis of luminal ILC between the CT and non-CT groups.

Results

For all subtypes, the disease-free survival (DFS) and overall survival (OS) of ILC were poorer than those of IDC. In the analysis by each subtype, no statistically significant difference was found in DFS and OS in luminal human epidermal growth factor 2 (HER2), HER2, and triple-negative cohorts; however, luminal ILC had significantly poorer DFS and OS than luminal IDC. The CT effects on the prognosis of luminal ILC were greater in more advanced cases.

Conclusion

Luminal ILC had a poorer prognosis than luminal IDC, contributing to the worse prognosis of ILC than that of IDC in the overall cohort. Different therapeutic approaches from luminal IDC are essential for a better prognosis of luminal ILC.

Cristofanilli M, Gonzalez-Angulo A, Sneige N et al (2005) Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 23:41–48. https://doi.org/10.1200/JCO.2005.03.111CrossRefPubMed

Van Baelen K, Geukens T, Maetens M et al (2022) Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. Ann Oncol 33:769–785. https://doi.org/10.1016/j.annonc.2022.05.006CrossRefPubMed

Mouabbi JA, Hassan A, Lim B, Hortobagyi GN, Tripathy D, Layman RM (2022) Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. Breast Cancer Res Treat 193:253–264. https://doi.org/10.1007/s10549-022-06572-wCrossRefPubMed

Pestalozzi BC, Zahrieh D, Mallon E et al (2008) Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 international breast Cancer Study Group clinical trials. J Clin Oncol 26:3006–3014. https://doi.org/10.1200/JCO.2007.14.9336CrossRefPubMed

Adachi Y, Ishiguro J, Kotani H et al (2016) Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma. BMC Cancer 16:248. https://doi.org/10.1186/s12885-016-2275-4CrossRefPubMedPubMedCentral

Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418–8423. https://doi.org/10.1073/pnas.0932692100CrossRefPubMedPubMedCentral

Iorfida M, Maiorano E, Orvieto E et al (2012) Invasive lobular breast cancer: subtypes and outcome. Breast Cancer Res Treat 133:713–723. https://doi.org/10.1007/s10549-012-2002-zCrossRefPubMed

Carey LA, Dees EC, Sawyer L et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329–2334. https://doi.org/10.1158/1078-0432.CCR-06-1109CrossRefPubMed

Kubo M, Kumamaru H, Isozumi U et al (2020) Annual report of the japanese breast Cancer Society registry for 2016. Breast Cancer 27:511–518. https://doi.org/10.1007/s12282-020-01081-4CrossRefPubMed

10.

Hayashi N, Kumamaru H, Isozumi U et al (2020) Annual report of the japanese breast Cancer Registry for 2017. Breast Cancer 27:803–809. https://doi.org/10.1007/s12282-020-01139-3CrossRefPubMed

11.

Miyata H, Gotoh M, Hashimoto H et al (2014) Challenges and prospects of a clinical database linked to the board certification system. Surg Today 44:1991–1999. https://doi.org/10.1007/s00595-013-0802-3CrossRefPubMed

12.

Greene (2003) AJCC cancer staging manual. Springer, New York

13.

Organization WH (2003) Tumours of the breast and female genital organs. Oxford University Press, Oxford

14.

Yang C, Lei C, Zhang Y et al (2020) Comparison of overall survival between invasive lobular breast carcinoma and invasive ductal breast carcinoma: a propensity score matching study based on SEER Database. Front Oncol 10:590643. https://doi.org/10.3389/fonc.2020.590643CrossRefPubMedPubMedCentral

15.

Xiao Y, Ma D, Ruan M et al (2017) Mixed invasive ductal and lobular carcinoma has distinct clinical features and predicts worse prognosis when stratified by estrogen receptor status. Sci Rep 7:10380. https://doi.org/10.1038/s41598-017-10789-xCrossRefPubMedPubMedCentral

16.

Chen Z, Yang J, Li S et al (2017) Invasive lobular carcinoma of the breast: a special histological type compared with invasive ductal carcinoma. PLoS ONE 12:e0182397. https://doi.org/10.1371/journal.pone.0182397CrossRefPubMedPubMedCentral

17.

Lim ST, Yu JH, Park HK, Moon BI, Ko BK, Suh YJ (2014) A comparison of the clinical outcomes of patients with invasive lobular carcinoma and invasive ductal carcinoma of the breast according to molecular subtype in a korean population. World J Surg Oncol 12:56. https://doi.org/10.1186/1477-7819-12-56CrossRefPubMedPubMedCentral

18.

Engstrom MJ, Opdahl S, Vatten LJ, Haugen OA, Bofin AM (2015) Invasive lobular breast cancer: the prognostic impact of histopathological grade, E-cadherin and molecular subtypes. Histopathology 66:409–419. https://doi.org/10.1111/his.12572CrossRefPubMed

19.

Weiser R, Polychronopoulou E, Hatch SS et al (2022) Adjuvant chemotherapy in patients with invasive lobular carcinoma and use of the 21-gene recurrence score: a National Cancer database analysis. Cancer 128:1738–1747. https://doi.org/10.1002/cncr.34127CrossRefPubMed

20.

Richard F, Majjaj S, Venet D et al (2020) Characterization of stromal tumor-infiltrating lymphocytes and genomic alterations in metastatic lobular breast Cancer. Clin Cancer Res 26:6254–6265. https://doi.org/10.1158/1078-0432.CCR-20-2268CrossRefPubMed

21.

Hanker AB, Sudhan DR, Arteaga CL (2020) Overcoming endocrine resistance in breast Cancer. Cancer Cell 37:496–513. https://doi.org/10.1016/j.ccell.2020.03.009CrossRefPubMedPubMedCentral

22.

Metzger Filho O, Giobbie-Hurder A, Mallon E et al (2015) Relative effectiveness of Letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1–98 trial. J Clin Oncol 33:2772–2779. https://doi.org/10.1200/JCO.2015.60.8133CrossRefPubMedPubMedCentral

23.

Strasser-Weippl K, Sudan G, Ramjeesingh R et al (2018) Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27. Eur J Cancer 90:19–25. https://doi.org/10.1016/j.ejca.2017.11.014CrossRefPubMed

24.

Marmor S, Hui JYC, Huang JL et al (2017) Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast. Cancer 123:3015–3021. https://doi.org/10.1002/cncr.30699CrossRefPubMed

25.

de Nonneville A, Jauffret C, Goncalves A et al (2019) Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit. Breast Cancer Res Treat 175:379–387. https://doi.org/10.1007/s10549-019-05160-9CrossRefPubMed

26.

Trapani D, Gandini S, Corti C et al (2021) Benefit of adjuvant chemotherapy in patients with lobular breast cancer: a systematic review of the literature and metanalysis. Cancer Treat Rev 97:102205. https://doi.org/10.1016/j.ctrv.2021.102205CrossRefPubMed

27.

McCart Reed AE, Kalinowski L, Simpson PT, Lakhani SR (2021) Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. Breast Cancer Res 23:6. https://doi.org/10.1186/s13058-020-01384-6CrossRefPubMedPubMedCentral

28.

Singh K, He X, Kalife ET, Ehdaivand S, Wang Y, Sung CJ (2018) Relationship of histologic grade and histologic subtype with oncotype dx recurrence score; retrospective review of 863 breast cancer oncotype dx results. Breast Cancer Res Treat 168:29–34. https://doi.org/10.1007/s10549-017-4619-4CrossRefPubMed

29.

Kizy S, Huang JL, Marmor S, Tuttle TM, Hui JYC (2017) Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast. Breast Cancer Res Treat 165:757–763. https://doi.org/10.1007/s10549-017-4355-9CrossRefPubMed

30.

Metzger O, Cardoso F, Poncet C et al (2020) Clinical utility of MammaPrint testing in Invasive Lobular Carcinoma: results from the MINDACT phase III trial. Eur J Cancer 138:S5–S6. https://doi.org/10.1016/S0959-8049(20)30542-6CrossRef

31.

Christgen M, Gluz O, Harbeck N et al (2020) Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer. Cancer 126:4847–4858. https://doi.org/10.1002/cncr.33104CrossRefPubMed

32.

Rakha EA, Reis-Filho JS, Baehner F et al (2010) Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 12:207. https://doi.org/10.1186/bcr2607CrossRefPubMedPubMedCentral

33.

Oesterreich S, Nasrazadani A, Zou J et al (2022) Clinicopathological features and outcomes comparing patients with invasive ductal and lobular breast Cancer. J Natl Cancer Inst 114:1511–1522. https://doi.org/10.1093/jnci/djac157CrossRefPubMed

34.

Wilson IB, Cleary PD (1995) Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA 273:59–65CrossRefPubMed

Titel: Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry
verfasst von: Yayoi Adachi
Sota Asaga
Hiraku Kumamaru
Naoko Kinugawa
Yasuaki Sagara
Naoki Niikura
Hiromitsu Jinno
Shigehira Saji
Masakazu Toi
Publikationsdatum: 21.07.2023
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2023
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-023-07022-x

Springer Medizin

Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry